Advances in Mammalian Cell Line Development Technologies for Recombinant Protein Production

From 2006 to 2011, an average of 15 novel recombinant protein therapeutics have been approved by US Food and Drug Administration (FDA) annually. In addition, the expiration of blockbuster biologics has also spurred the emergence of biosimilars. The increasing numbers of innovator biologic products a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Tingfeng, Yang, Yuansheng, Ng, Say Kong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817724/
https://www.ncbi.nlm.nih.gov/pubmed/24276168
http://dx.doi.org/10.3390/ph6050579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817724/
https://www.ncbi.nlm.nih.gov/pubmed/24276168
http://dx.doi.org/10.3390/ph6050579

Ejemplares similares